Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dutasteride reduces DHT more effectively than finasteride.

MK-386 reduces sebum DHT levels.

This study examined lawsuits in Canada involving 5α-reductase inhibitors, revealing that all cases related to persistent erectile dysfunction as a side effect in men treated for hair loss, but no judgments have been made yet against physicians or pharmaceutical companies.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.

This study found that despite the presence of steroidogenesis inhibitors, CRPC tumor cells adapt to continue synthesizing androgens, suggesting a need for more effective androgen axis targeting.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This study found that testosterone is converted to estrogenic steroids in vitro without aromatase involvement, suggesting that combining 5α-reductase and aromatase inhibitors might reduce estrogenic steroids more completely in vivo.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This study observed that aromatase inhibitors caused hair loss in menopausal women with breast cancer, mimicking male pattern baldness rather than female androgenetic alopecia.

This study confirms that finasteride inhibits the conversion of testosterone to dihydrotestosterone in human dermal fibroblasts, suggesting potential therapeutic use for androgen-related skin disorders.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This mini review explores the potential of herbal testosterone 5α-reductase inhibitors for treating androgenetic alopecia, suggesting they might offer fewer side effects and better tolerability than traditional treatments like finasteride and minoxidil.

In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.

This case report documents successful virilization, including penile length increase, in a boy with partial androgen insensitivity syndrome using high-dose testosterone combined with anastrozole.

In this study, DHT was found to inhibit hair growth in mice by decreasing IGF-I production in dermal papillae through reduced sensory neuron stimulation.

Finasteride reduces melanin production in skin cells.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.

This study found that oral administration of finasteride to pregnant rats caused dosage-related developmental toxicities, including hypospadias and decreased anogenital distance in male offspring.

Both drugs lower DHT levels, with GI198745 being more effective.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This study found that dual 5α-reductase inhibitors in rats decreased sperm quality and led to reduced pregnancy success, suggesting potential for use in male contraception.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.